Research progress of miroRNA in the mechanism of cardiac hypertrophy and its role as new drug targets
10.3760/cma.j.cn121382-20210620-00612
- VernacularTitle:微小RNA在心肌肥厚中的作用机制及其作为新药靶点的研究进展
- Author:
Shuanglin WANG
1
;
Jingjing YANG
;
Zexing LI
;
Hui ZHOU
;
Bing YANG
;
Peng ZHANG
Author Information
1. 天津医科大学总医院心胸外科 300052
- Keywords:
microRNA;
Cardiac hypertrophy;
Noncoding RNA
- From:
International Journal of Biomedical Engineering
2021;44(6):486-490
- CountryChina
- Language:Chinese
-
Abstract:
Cardiac hypertrophy is a common physiological or pathological process, and pathological cardiac hypertrophy can lead to heart failure, sudden death, etc. The role of microRNA (miRNA or MIR) in myocardial hypertrophy has gradually attracted public attention. miR-1 plays a certain protective role in the occurrence of cardiac hypertrophy. miR-133 is a key factor in the establishment of mast gene program, which is very important for the development of myocardial hypertrophy. Carvedilol and other drugs can regulate the expression of miR-133. miR-208a plays an important physiological role in the cardiovascular system, and its expression level changes dynamically in a variety of cardiovascular diseases such as cardiac hypertrophy, which is closely related to the progression and prognosis of the disease. The expression of miR-199a is up-regulated in pressure-overload cardiac hypertrophy, and it is found that miR-199a can inhibit autophagy of cardiomyocytes and induce the occurrence of cardiac hypertrophy. miR-200c can protect cardiomyocytes through a variety of pathways. miRNA may become an important biomarker or drug therapeutic target for cardiac hypertrophy. With the deepening of the research on non-coding RNAs including miRNA, its regulation on the occurrence of cardiac hypertrophy and the pathological process of heart failure will be further revealed.
